Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel…
BUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel…